Scapular Mobilization Added to Conventional Exercise in Ankylosing Spondylitis

November 13, 2026 updated by: Elif Umay Altas, Izmir Bakircay University

The Effect of Scapular Mobilization Added to Conventional Exercises on Respiratory Function, Posture, and Quality of Life in Patients With Ankylosing Spondylitis: A Randomized Controlled Trial

Ankylosing spondylitis (AS) is a chronic inflammatory disease of the axial skeleton that commonly leads to restricted spinal mobility, postural deformities such as thoracic hyperkyphosis, and reduced chest wall expansion, which can impair respiratory function and quality of life. Exercise is the cornerstone of rehabilitation in AS, and manual therapy techniques may provide additional benefit by restoring mobility of the thoracic cage and shoulder girdle.

The aim of this randomized controlled, single-blind trial is to investigate whether scapular mobilization added to a conventional exercise program improves chest expansion and respiratory function (primary outcomes), as well as pain, disease activity, function, spinal mobility, posture, exercise capacity, and quality of life (secondary outcomes) in patients with AS. Thirty-four patients will be randomly allocated to either scapular mobilization plus conventional exercise or conventional exercise alone, 3 sessions per week for 8 weeks (24 sessions). Outcomes will be assessed at baseline, after treatment (week 8), and at month 3.

Study Overview

Detailed Description

Background: AS is a chronic inflammatory disease most frequently seen in young men, involving the spine, sacroiliac joints, peripheral joints, and entheses, and causing pain, stiffness, functional impairment, and postural abnormalities. Dysfunction of the thoracic spine and scapular region not only causes pain and limited movement but also restricts chest wall mobility, which may reduce ventilatory efficiency and quality of life. Previous studies have shown that thoracic mobilization exercises improve kyphosis and respiratory function (FVC, FEV1), aerobic exercise improves disease activity and respiratory muscle strength, and manual therapy added to exercise provides superior improvements in chest expansion and functional capacity. However, evidence on the specific added contribution of scapular mobilization to standard exercise programs is limited.

Design: Prospective, randomized, controlled, single-blind, parallel-group trial conducted at the Physical Medicine and Rehabilitation outpatient clinic of Izmir Bakircay University Cigli Training and Research Hospital.

Sample size: Based on Acharya et al. (2024), with an effect size of Cohen's d = 0.40, alpha = 0.05, power = 80%, a two-group repeated-measures design with three time points and a correlation of 0.3 between repeated measures, the minimum sample size is 30 (15 per group). Allowing for a 10% dropout rate, 34 participants (17 per group) will be enrolled.

Interventions: Both groups will receive the same progressive conventional exercise program (30 minutes per session, 3 sessions/week, 8 weeks, 24 sessions), supervised by the same physiotherapist. The experimental group will additionally receive approximately 20 minutes of scapular mobilization per session.

Conventional exercise program: posture and patient education (spinal alignment, deep spinal muscle activation, chin-tuck position); warm-up and cool-down (active range-of-motion exercises, 10 repetitions each); stretching (hamstrings, pectorals, child's pose for thoracolumbar flexion; 30 s x 2 repetitions); mobility exercises (hook-lying lateral flexion to heels, cat-camel, side-lying thoracic rotation with arm movement); strengthening exercises (bridge, mini squat, prone Y/T/W, wall towel slide, resisted serratus punch, bird-dog, clamshell); and breathing exercises (unilateral, bilateral, apical, and posterior basal thoracic expansion exercises; segmental costal breathing; thoracic expansion combined with upper-extremity elevation).

Progression: Weeks 1-2 (initial level: movement learning, low-intensity mobility, breathing, stretching and low-resistance strengthening; 8-10 repetitions, 1-2 sets, slow tempo); weeks 3-5 (intermediate: increased repetitions and sets, dynamic movements, moderate elastic band resistance, breathing combined with arm movements; 10-15 repetitions, 2-3 sets, moderate tempo); weeks 6-8 (advanced: higher resistance, multi-joint functional movements, dynamic balance and coordination, increased aerobic duration; 12-15 repetitions, 3 sets, moderate-to-high tempo). Progression requires correct form, no increase in pain (VAS) during exercise, return of symptoms to baseline within 24 hours, and improved functional performance. Regression to the previous level occurs with increased pain, prolonged fatigue, postural deterioration, or compensatory movement patterns.

Scapular mobilization: Performed by a physiotherapist with the patient in side-lying. The therapist grasps the superior and inferior angles of the scapula to apply superior-inferior glides, followed by upward and downward rotation mobilizations. Then, grasping the inferior angle and medial border with both hands, the therapist tilts the scapula away from the thoracic wall while applying scapular distraction. Each technique is applied as 3 sets of 10 repetitions (6 seconds per cycle) with 30 seconds of rest between sets (Maitland approach).

Assessments: Demographic and clinical data (age, sex, height, weight, education, occupation, smoking/alcohol, family history, diagnosis year, symptom duration, medications and duration of use, extra-articular involvement, previous surgery, exercise habits) will be recorded. Outcome measures (VAS, BASDAI, BASFI, BASMI, ASQoL, chest expansion, spirometry, 6-minute walk test, thoracic kyphosis angle by digital inclinometer) will be assessed at baseline, after treatment (week 8), and at month 3.

Hypotheses: H0 - Scapular mobilization added to routine exercises has no effect on pain, posture, respiratory function, and quality of life in patients with AS. H1 - Scapular mobilization added to routine exercises has an effect on these parameters.

Statistical analysis: SPSS version 20.0 will be used, with p < 0.05 considered significant. Normality will be tested with the Kolmogorov-Smirnov test. Repeated-measures ANOVA will be used for parametric data; Friedman and Wilcoxon signed-rank tests for non-parametric data. Categorical variables will be compared using the chi-square test.

Study Type

Interventional

Enrollment (Estimated)

34

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Izmir, Turkey (Türkiye), 35620
        • Izmir Bakircay University Cigli Training and Research Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

30 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Diagnosis of ankylosing spondylitis according to the modified New York criteria
  • Age between 30 and 60 years
  • Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of 4.0 or lower
  • Pulmonary function test performed within the last month

Exclusion Criteria:

  • Regular exercise during the previous 3 months
  • Spinal ankylosis
  • Cardiovascular, pulmonary, orthopedic, or neurological conditions that may prevent exercise (uncontrolled hypertension, history of myocardial infarction or coronary revascularization, history of syncope or exercise-related arrhythmia, decompensated type 1 diabetes mellitus, history of hip and/or knee arthroplasty)
  • Any surgery within the last 6 months
  • Active disease flare within the last 3 months
  • Communication problems
  • Any other respiratory or neuromuscular disease that may affect the respiratory muscles

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Scapular Mobilization + Conventional Exercise

Performed by a physiotherapist with the patient in side-lying. The therapist grasps the superior and inferior angles of the scapula to apply superior-inferior glides, followed by upward and downward rotation mobilizations. Then, grasping the inferior angle and medial border with both hands, the therapist tilts the scapula away from the thoracic wall while applying scapular distraction. Each technique is applied as 3 sets of 10 repetitions (6 seconds per cycle) with 30 seconds of rest between sets (Maitland approach).

Performed by a physiotherapist with the patient in side-lying. The therapist grasps the superior and inferior angles of the scapula to apply superior-inferior glides, followed by upward and downward rotation mobilizations. Then, grasping the inferior angle and medial border with both hands, the therapist tilts the scapula away from the thoracic wall while applying scapular distraction. Each technique is applied as 3 sets of 10 repetitions (6 seconds per cycle) with 30 seconds of rest between sets (Maitland approach).

Other Names:
  • Maitland scapular mobilization

posture and patient education (spinal alignment, deep spinal muscle activation, chin-tuck position); warm-up and cool-down (active range-of-motion exercises, 10 repetitions each); stretching (hamstrings, pectorals, child's pose for thoracolumbar flexion; 30 s x 2 repetitions); mobility exercises (hook-lying lateral flexion to heels, cat-camel, side-lying thoracic rotation with arm movement); strengthening exercises (bridge, mini squat, prone Y/T/W, wall towel slide, resisted serratus punch, bird-dog, clamshell); and breathing exercises (unilateral, bilateral, apical, and posterior basal thoracic expansion exercises; segmental costal breathing; thoracic expansion combined with upper-extremity elevation).

Other Names:
  • Standard exercise therapy
Active Comparator: Conventional Exercise

Conventional exercise program: posture and patient education (spinal alignment, deep spinal muscle activation, chin-tuck position); warm-up and cool-down (active range-of-motion exercises, 10 repetitions each); stretching (hamstrings, pectorals, child's pose for thoracolumbar flexion; 30 s x 2 repetitions); mobility exercises (hook-lying lateral flexion to heels, cat-camel, side-lying thoracic rotation with arm movement); strengthening exercises (bridge, mini squat, prone Y/T/W, wall towel slide, resisted serratus punch, bird-dog, clamshell); and breathing exercises (unilateral, bilateral, apical, and posterior basal thoracic expansion exercises; segmental costal breathing; thoracic expansion combined with upper-extremity elevation).

posture and patient education (spinal alignment, deep spinal muscle activation, chin-tuck position); warm-up and cool-down (active range-of-motion exercises, 10 repetitions each); stretching (hamstrings, pectorals, child's pose for thoracolumbar flexion; 30 s x 2 repetitions); mobility exercises (hook-lying lateral flexion to heels, cat-camel, side-lying thoracic rotation with arm movement); strengthening exercises (bridge, mini squat, prone Y/T/W, wall towel slide, resisted serratus punch, bird-dog, clamshell); and breathing exercises (unilateral, bilateral, apical, and posterior basal thoracic expansion exercises; segmental costal breathing; thoracic expansion combined with upper-extremity elevation).

Other Names:
  • Standard exercise therapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Chest Expansion
Time Frame: Baseline, week 8 (end of treatment), and month 3
Baseline, week 8 (end of treatment), and month 3
Forced Vital Capacity (FVC)
Time Frame: Baseline, week 8 (end of treatment), and month 3
Baseline, week 8 (end of treatment), and month 3
Forced Expiratory Volume in 1 Second (FEV1)
Time Frame: Baseline, week 8 (end of treatment), and month 3
Baseline, week 8 (end of treatment), and month 3
FEV1/FVC Ratio
Time Frame: Baseline, week 8 (end of treatment), and month 3
Baseline, week 8 (end of treatment), and month 3

Secondary Outcome Measures

Outcome Measure
Time Frame
Peak Expiratory Flow (PEF)
Time Frame: Baseline, week 8 (end of treatment), and month 3
Baseline, week 8 (end of treatment), and month 3
Thoracic Pain Intensity (Visual Analog Scale)
Time Frame: Baseline, week 8 (end of treatment), and month 3
Baseline, week 8 (end of treatment), and month 3
Disease Activity (BASDAI)
Time Frame: Baseline, week 8 (end of treatment), and month 3
Baseline, week 8 (end of treatment), and month 3
Functional Status (BASFI)
Time Frame: Baseline, week 8 (end of treatment), and month 3
Baseline, week 8 (end of treatment), and month 3
Spinal Mobility (BASMI)
Time Frame: Baseline, week 8 (end of treatment), and month 3
Baseline, week 8 (end of treatment), and month 3
Quality of Life (ASQoL)
Time Frame: Baseline, week 8 (end of treatment), and month 3
Baseline, week 8 (end of treatment), and month 3
Thoracic Kyphosis Angle
Time Frame: Baseline, week 8 (end of treatment), and month 3
Baseline, week 8 (end of treatment), and month 3
Functional Exercise Capacity (6-Minute Walk Test)
Time Frame: Baseline, week 8 (end of treatment), and month 3
Baseline, week 8 (end of treatment), and month 3

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Elif Umay Altaş, Izmir Bakircay University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 16, 2026

Primary Completion (Estimated)

November 16, 2027

Study Completion (Estimated)

November 25, 2027

Study Registration Dates

First Submitted

November 13, 2026

First Submitted That Met QC Criteria

November 13, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 13, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

De-identified individual participant data will not be made publicly available but can be shared with qualified researchers upon reasonable request to the principal investigator.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe